Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Eur Rev Med Pharmacol Sci ; 25(12): 4400-4404, 2021 06.
Article in English | MEDLINE | ID: mdl-34227075

ABSTRACT

OBJECTIVE: Celiac disease (CD) is an autoimmune disorder, characterized by increased susceptibility to bacterial and viral infections. Therefore, the CD patients could be exposed to an increased risk of contracting SARS-CoV-2, a virus for which the WHO declared a pandemic status in March 2020. This study aims to investigate the incidence of SARS-CoV-2 infection in CD patients, to assess the impact of CD on the risk of contracting this virus. PATIENTS AND METHODS: This retrospective multicentric cohort study evaluated 542 celiac patients, who answered a questionnaire concerning both the underlying disease (adherence to the gluten-free diet, residual symptoms) and the possible SARS-CoV-2 infection (swab outcome, presence and characteristics of symptoms and type of treatment received), referring to the period between 20th January 2020 and 27th October 2020. RESULTS: Five patients (0.92%) tested positive; of these, 2 were asymptomatic and 3 developed symptoms of COVID-19. The incidence of SARS-CoV-2 infection in CD patients was not significantly different from the general population. The ratio of positive/diagnostic swabs tends to be higher in CD patients than in the general population (IR: 0.15; 0.06; p=0.06), whereas the number of subjects who performed the swab in this group is significantly lower (IR: 0.06; 0.15; p<0.001). CONCLUSIONS: Although CD patients are more susceptible to infections, the incidence of SARS-CoV-2 infection in our sample was not significantly different from the general population. However, the positive/diagnostic swabs ratio seems to be higher, probably also due to the lower number of patients tested.


Subject(s)
COVID-19/diagnosis , COVID-19/epidemiology , Celiac Disease/diagnosis , Celiac Disease/epidemiology , COVID-19/therapy , COVID-19 Testing/methods , Celiac Disease/therapy , Cohort Studies , Diet, Gluten-Free/methods , Humans , Italy/epidemiology , Retrospective Studies
2.
Eur Rev Med Pharmacol Sci ; 23(19): 8625-8629, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31646596

ABSTRACT

OBJECTIVE: Cannabis is an illegal drug that has been under the spotlight in recent years, due to its vast array of effects on different biological systems. The role of cannabis has been investigated in the management of pain in acute pancreatitis (AP), even though some studies suggest that it may have a causative effect in this pathology and could be considered the underlying etiology in some cases of idiopathic AP. In this case report, we discuss the case of a young man who presented with three different episodes of AP, with apparently no significant history of alcohol and drug consumption, and with no evidence of a biliary, genetic or, autoimmune etiology. During the third episode, in which he had developed a voluminous pseudocyst, treated trough ultrasound (EUS)-guided drainage, he admitted consumption of cannabis daily. The Naranjo score resulted to be 6 (confirming the possible causality), and it was suggested to the patient to avoid cannabis consumption. Since then, he did not develop any other AP episodes. In summary, cannabis should be considered among the possible AP etiologies, as its causative identification and interruption may significantly improve the course of several idiopathic APs.


Subject(s)
Cannabinoids/adverse effects , Cannabis/adverse effects , Pancreatitis/chemically induced , Adult , Humans , Male , Pancreatitis/diagnostic imaging
3.
Eur Rev Med Pharmacol Sci ; 23(2): 771-787, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30720186

ABSTRACT

Acute pancreatitis (AP) is the most common gastrointestinal disorder requiring hospitalization, with a high rate of morbidity and mortality. Severe AP is characterized by the presence of persistent organ failure involving single or multiple organs. Clinical evolution, laboratory and radiological assessment are necessary to evaluate the prognosis and inform the management of AP. The onset of severe AP may be classified in two principal phases. The early phase, during the first week, is characterized by the activation of the auto-inflammatory cascade, gut dysbiosis, bacterial translocation, and the down-regulation of immune responses. The late phase is characterized by the development of local and systemic complications. Several old paradigms have been amended in the management of AP patients, such as the indication of nutrition, the use of antibiotic therapy, pain control strategies, and even the use of surgery. Real world evidence has shown that in the majority of cases a step-up approach is most effective. In this review, we discuss the clinical assessment and improvements to the management of patients with severe AP in a high volume center where a multi-disciplinary approach is performed.


Subject(s)
Multiple Organ Failure/therapy , Pain/drug therapy , Pancreatitis/therapy , Patient Care Team , Analgesics/therapeutic use , Anti-Bacterial Agents/therapeutic use , Bacterial Translocation/immunology , Cholangiopancreatography, Endoscopic Retrograde , Drainage/methods , Gastroenterostomy , Gastrointestinal Microbiome/immunology , Humans , Multiple Organ Failure/immunology , Nutrition Therapy/methods , Pain/immunology , Pain Management/methods , Pancreas/diagnostic imaging , Pancreas/immunology , Pancreas/pathology , Pancreas/surgery , Pancreatitis/complications , Pancreatitis/diagnosis , Pancreatitis/immunology , Severity of Illness Index , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...